Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Sant P ChawlaBrian Andrew Van TineSeth M PollackKristen N GanjooAnthony D EliasRichard F RiedelSteven AttiaEdwin ChoyScott H OkunoMark AgulnikMargaret von MehrenMichael B LivingstonVicki L KeedyClaire F VerschraegenTony PhilipG Chet BohacSergey YurasovAdam YakovichHailing LuMichael ChenRobert G MakiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Although the combination of CMB305 and atezolizumab did not result in significant increases in PFS or OS compared with atezolizumab alone, some patients demonstrated evidence of an anti-NY-ESO-1 immune response and appeared to fare better by imaging than those without such an immune response. Combining prime-boost vaccines such as CMB305 with anti-programmed death ligand-1 therapies merits further evaluation in other clinical contexts.